Cellentia, Inc.

Cellentia is developing a cutting-edge platform that uses circulating tumor cell-derived organoids for AI-assisted screening of novel drugs targeting metastatic solid tumors. This platform also facilitates longitudinal monitoring of emerging drug resistance and helps drug developers understand the biology of treatment responders and non-responders in clinical trials. By offering this platform and other novel bioassays as service, Cellentia empowers drug developers to accelerate their drug development and achieve better therapeutic outcomes.